Inpharma Weekly

, Volume 1088, Issue 1, pp 9–10 | Cite as

Pirfenidone & relaxin: 2 new hopes for fibrotic disease

  • Gill Higgins
Newsletter Article


Pirfenidone and relaxin are both under investigation for the treatment of fibrotic disease. At present, there are no effective cures for fibrotic disorders. Both agents are currently in phase II trials, pirfenidone for idiopathic pulmonary fibrosis (IPF) and relaxin for systemic sclerosis. Initial clinical results with these agents suggest that they may have therapeutic potential, and that they are better tolerated than current treatment options. Details of the 2 drugs were presented at the 2nd International IBC Conference on Fibrosis [ Washington DC, US; April 1997 ].


Ulcerative Colitis Colchicine Idiopathic Pulmonary Fibrosis Systemic Sclerosis Mesalazine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Adis International Ltd 1997

Authors and Affiliations

  • Gill Higgins

There are no affiliations available

Personalised recommendations